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ReviewBiological Control through
Regulated Transcriptional Coactivators
complex supports transcription in vitro from DNA tem-
plates but does not support efficient transcription from
chromatinized templates (reviewed in Malik and Roeder,
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2000). Lastly, protein complexes of the yeast SWI/SNFHarvard Medical School
family (or their mammalian homologs BRG1 or BRM)Boston, Massachusetts 02115
contain ATP-dependent DNA unwinding activities, nec-2 Institute of Biology
essary for efficient gene transcription in vivo. TheseSection of Theoretical Biophysics
groups of proteins will not support transcription fromHumboldt University
naked DNA, but augment transcription from chroma-10115 Berlin
tinized templates in vitro (Lemon et al., 2001). More bio-Germany
chemical activities of coactivator proteins are very likely
to be discovered.
Corepressors have the opposite effect on chromatinGene activation in higher eukaryotes requires the con-
structure, making it inaccessible to the binding of tran-certed action of transcription factors and coactivator
scription factors or resistant to their actions. These pro-proteins. Coactivators exist in multiprotein complexes
teins (such as NcoR) are often associated with histonethat dock on transcription factors and modify chroma-
deacetylase (HDAC) activity, though other mechanismstin, allowing effective transcription to take place. While
for gene silencing clearly exist (Hermanson et al., 2002).biological control focused at the level of the transcrip-
Although coactivators are defined as proteins thattion factor is very common, it is now quite clear that
increase transcriptional activity without binding to DNA,a substantial component of gene control is directed
it is useful to think of those that bind directly to transcrip-at the expression of coactivators, involving pathways
tion factors and contain relevant enzymatic activitiesas diverse as B-cell development, smooth muscle dif-
as primary coactivators (Figure 1). Those that dock onferentiation, and hepatic gluconeogenesis. Quantita-
transcription factors and serve as scaffolds for the re-tive control of coactivators allows the functional inte-
cruitment of other proteins containing these enzymaticgration of multiple transcription factors and facilitates
activities can be considered secondary coactivators. Asthe formation of distinct biological programs. This co-
shown in Figure 1 and discussed below, this distinctionordination and acceleration of different steps in linked
rapidly blurs as proteins that can function as primarypathways has important kinetic considerations, en-
coactivators on some transcription factors can also beabling outputs of particular pathways to be increased
used as enzymatic tools assembled by secondary co-far more than would otherwise be possible. These ki-
activators in other contexts.netic aspects suggest opportunities and concerns as
The regulation of gene activity at the transcriptionalcoactivators become targets of therapeutic inter-
level has generally been thought to occur via changesvention.
in amounts or activities of transcription factors. In this
view, transcription factors may themselves be transcrip-
tionally induced or repressed, and activated or deacti-Introduction
vated by proteolysis, covalent modification, or ligandGene activation is a multistep process involving a very
binding. The control of nuclear NFB through pathways
large number of proteins functioning in discrete com-
of signal transduction in inflammation and the induction
plexes. Transcription factors bind to DNA in a sequence-
of the myogenic b-HLH proteins, such as MyoD, during
specific manner and essentially mark a gene for activa- muscle differentiation are classic examples of biologi-
tion or repression through the recruitment of coactivator cal control through modulation of transcription factor
or corepressor proteins. Coactivators function in a vari- quantity.
ety of ways and often contain the enzymatic activities However, recent data has shown that important physi-
necessary for an alteration in chromatin structure from ological control of gene regulatory systems is not solely
a quiescent state to one allowing active gene transcrip- the province of transcription factors. Coactivator pro-
tion. Broadly speaking, coactivators can be thought of teins may participate in gene regulation, not merely by
in three classes. One class of proteins modifies histones being necessary gears in the transcriptional machinery,
in ways that allow greater access of other proteins to but by being the primary targets of developmental or
the DNA. Examples of these are p300 and CBP, powerful physiological signals. In this review, we will discuss data
histone acetyltransferases (HATs) that interact with a illustrating complex biological processes controlled at
wide variety of transcription factors and other proteins the coactivator level. While posttranslation modification
(Hermanson et al., 2002). These proteins support tran- of coactivator proteins occurs and represents an emerg-
scription in vitro from chromatinized templates. A sec- ing area of discovery, we will concentrate on several
ond class of coactivators are members of the TRAP/ examples of modulation of coactivator expression in
DRIP/Mediator/ARC complex, proteins that bind to tran- various biological settings. We have chosen to discuss
scription factors, recruit RNA polymerase II and interact in detail those examples where the coactivation function
with the general transcription apparatus. The Mediator of a given protein or set of proteins is very well estab-
lished, and where the regulation in physiological settings
is a key part of the significance of that coactivator. This*Correspondence: bruce_spiegelman@dfci.harvard.edu
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Figure 1. Flexible Nature of Coactivator Pro-
teins
Certain coactivator proteins, such as CBP,
contain HAT activity and bind directly to tran-
scription factors (TF), as well as recruit other
HATs like SRC-1 and pCAF. In addition to
serving as a primary coactivator, as in the left
panel, CBP can also function as an accessory
protein to a secondary coactivator like
PGC-1, shown on the right, which binds to
transcription factors but must rely on CBP,
SRC-1, and other factors for enzymatic modi-
fications of chromatin.
mode of regulation has important implications for as well. Whether and how recruitment of these proteins
results in chromatin modifications remains to be deter-allowing higher-level organization of gene networks into
complex biological programs. There have been several mined. Interestingly, besides the nuclear form of OCA-B
(p34), OCA-B is also expressed as a 35 KDn protein thatexcellent recent reviews on biochemical aspects of tran-
scriptional coactivators (Hermanson et al., 2002; Mc- is inserted into the plasma membrane (Yu et al., 2004).
As expected, the membrane bound form of OCA-B doesKenna and O’Malley, 2002; Fischle et al., 2003), so these
important facets of coactivator biology will be dealt with not stimulate transcription. Its physiological significance
remains unclear.relatively briefly here. For a comprehensive table of co-
activator proteins, see Hermanson et al. (2002). There
are fewer examples of biological control through regu- Friend of GATA (FOG)
GATA factors, particularly GATA-1, 2, and 3, are impor-lated corepressors but these also exist (e.g., RIP140
and MTA3; Leonardsson et al., 2004; Fujita et al., 2004). tant for the development of various hematopoetic lin-
eages (reviewed in Fossett and Schulz, 2001). WhileMany of the principles of coactivators discussed here,
particularly concerning kinetic considerations, also the GATA factors are highly homologous in their DNA
binding domains, structure-function analyses suggestedapply to this class of proteins.
that the N terminus of GATA-1 is required for the differ-
entiation of erythroid cells. A yeast two-hybrid screenOCA-B and B-Cell Function
Studies of the immunoglobulin (Ig) gene promoters indi- with the N-terminal region of GATA-1 yielded Friend of
GATA, or FOG, a coactivator protein that is highly ex-cated an important role for octamer binding proteins
(Oct) in regulation of the Ig genes. While Oct-1 is widely pressed in erythroid cells and megakaryocytes (Tsang et
al., 1997). Whereas genetic ablation of GATA-1 in miceexpressed in many tissues, the expression of Oct-2 is
largely restricted to B cells. This suggested a simple leads to a block in megakaryocyte development in mid-
maturation (Shivdasani et al., 1997), knockout of FOGmodel whereby expression of Oct-2 would trigger pref-
erential activation of the Ig genes in B cells. However, (now FOG-1) prevents megakaryocyte formation alto-
gether (Tsang et al., 1998), suggesting that FOG-1 hasalthough Oct-2 can stimulate expression from artificial
B cell promoters, this factor proved unable to activate a broader role in megakaryocyte development. With re-
gard to the erythroid lineage, ablation of GATA-1 ormore authentic Ig promoters in transfected cells or to
stimulate Ig transcription in cell-free systems. This led FOG-1 stops erythroid maturation at the proerythroid
stage, but even here there are differences. FOG-1 mu-to the biochemical purification of a protein, OCA-B,
which can interact with both Oct-1 and Oct-2 and stimu- tant erythroid precursors survive longer than GATA-1
mutant cells, suggesting again that FOG-1 might medi-late Ig gene transcription in vitro (Pierani, 1990; Luo and
Roeder, 1995). OCA-B is expressed in a highly B-cell ate GATA-1 independent effects through different tran-
scription factors and GATA-1 might have additionalselective manner and loss of function studies in mice
indicate clearly that OCA-B is required for Ig gene ex- coactivator partners.
FOG-2 is a protein with homology to FOG-1, but ispression. However, mice lacking OCA-B do not simply
produce normal B-cells lacking Ig production; they are expressed in nonhematopoietic tissues such as devel-
oping gonadal, cardiac, and nervous tissues (Lu et al.,also deficient in the formation of germinal centers (Kim
et al., 1996; Nielsen et al., 1996; Schubart et al., 1996). 1999; Svensson et al., 1999; Tevosian et al., 2000; Cris-
pino et al., 1999). FOG-2 knockout mice die midgestationThese two events are known to be independent events
in B-cell development. Hence, it is almost certain that of a cardiac defect (Tevosian et al., 2000). Knockin mice,
carrying an allele of GATA-1 that does not permit interac-OCA-B must participate in other signaling pathways,
dependent on or independent of Oct-1 and Oct-2. tion between GATA-1 and FOG proteins, showed devel-
opment of embryos to a later stage where defects inMechanistically, it seems clear that the OCA-B is a
class 2 coactivator in that it has not been shown to gonadal development could also be observed. This
clearly indicates that GATA-1 is not completely depen-possess intrinsic chromatin modifying enzymatic activi-
ties. Rather, it docks on Oct proteins and recruits other dent upon FOG proteins for its function.
The mechanism of action of FOG-1 has been studiedrequired factors (notably PC-4 and TAFII105) to a tran-
scriptional complex anchored on DNA (Luo et al., 1998; and appears quite interesting. GATA-2 expression is
ordinarily turned down during erythropoiesis as GATA-1Wolstein et al., 2000). OCA-B undoubtedly directs the
recruitment of other essential proteins to this complex rises. Indeed, GATA-1 appears to suppress the expres-
Review
159
sion of GATA-2. This ability of GATA-1 to suppress (Wang et al., 2001). What is clear is that this transcrip-
tional activation domain can work in a heterologousGATA-2 is dependent on FOG-1. This has led to the
context, linked to a Gal-4 DNA binding domain. This issuggestion that FOG-1 participates as a “chromatin-
at least suggestive of a transcriptional activation mecha-occupancy facilitator,” binding to the relevant GATA
nism of general utility, such as through the acetylationproteins and facilitating a switch on the GATA-2 pro-
of histones.moter from GATA-2 to GATA-1 (Pal et al., 2004). While
these authors envision a rather direct mechanism, it is
SRCalso possible that FOG-1 works via more conventional
A major leap in the understanding of nuclear receptorchromatin remodeling, which indirectly facilitates the
function came from data which showed clearly that therebinding of GATA-1 at the expense of GATA-2.
was a set of proteins that interacted with the estrogenInterestingly, FOG-2 has been shown to be capable
receptor in a ligand-dependent manner (Halachmi et al.,of activity as a corepressor, as well as a coactivator (Lu
1994). This started cloning efforts that identified manyet al., 1999; Clabby et al., 2003; Svensson et al., 2000).
coactivator and corepressor proteins including the SRCThe molecular mechanisms of repression, as well as the
family, now including SRC-1, SRC-2, and SRC-3 (re-means by which this protein can switch from a coactiva-
viewed by Xu and O’Malley, 2002). These proteins aretor to a corepressor, are not understood.
widely expressed and coactivate many if not most nu-
clear receptors, both classic steroid hormone receptorsMyocardin
as well as the “orphan” nuclear receptors. In terms ofSerum response factor (SRF) is a transcription factor
biological function, it is clear that they are of specialthat binds to many muscle cell promoters through so-
interest in steroid hormone action. SRC-1 knockoutcalled CarG boxes (Shore and Sharrocks, 1995). How-
mice show multiple, partial hormone resistance, andever, SRF binding sites are not muscle-specific, nor is
defects in the testes, prostate, uterus, and mammarySRF itself expressed preferentially in muscle. This led
gland (Xu et al., 1998).to a search for SRF partner proteins, which might endow
SRC-3, also known as pCIP, RAC3, ACTR, and AIB1muscle-selective activity to this factor. In silico analyses
(Torchia et al., 1997; Li et al., 1997; Chen et al., 1997;pointed to myocardin, a SAP domain-containing protein
Anzick et al., 1997; Takeshita et al., 1997; Suen et al.,that is expressed specifically in smooth muscle and
1998) is of particular note because it shows dramaticheart (Wang et al., 2001). Myocardin interacts with SRF
regulation in cancer, especially in prostate and breastphysically and is a very powerful coactivator. Analysis
tumors. Extremely high levels of SRC-3 are found inof myocardin’s biological function has utilized both a
breast cancer cell lines and tumors, secondary to ampli-dominant-negative allele and gene ablation in mice. Mi-
fication of this locus on the long arm of human chromo-croinjection of the dominant-negative allele of myocar-
some 20 (Anzick et al., 1997). From these observations,din into 8-cell Xenopus embryos caused a reduction in
much effort has gone into determining the role of SRC-3the normal expression of cardiac-selective molecular
in estrogen action, particularly the role of estrogen inmarkers such as -tropomyosin, cardiac -actin, and
stimulating the growth of breast cancer cells. SinceNkx2.5 (Wang et al., 2001). When myocardin was ex-
SRC-3 coactivates ER- more than ER-, it is tempting
pressed in cells already committed to the myogenic
to suggest that this pairing is important in the procancer
lineage, expression of smooth muscle markers like-SM
action of estrogens. In addition, there is evidence that
actin and calponin was elevated (Chen et al., 2002). SRC-3 may reduce the antitumor effects of tamoxifen
When myocardin was expressed in embryonic stem cells on the ER (Font de Mora et al., 2000).
or the nonmyogenic 10T1/2 cells, muscle differentiation While a major portion of the action of SRC-3 is un-
was observed with the formation of elongated mono- doubtedly via binding to the ER and other nuclear recep-
nucleated myocytes. Molecular analysis of the cultures tors, new data suggests that this coactivator also can
indicated that they have the characteristics of smooth bind to and coactivate the growth-regulating transcrip-
muscle, not skeletal or cardiac muscle (Fu et al., 2003; tion factor E2F1, providing another potential mechanism
Yoshida et al., 2003; Wang et al., 2003). This includes of action (Louie et al., 2004). The use of siRNAs directed
expression of specific molecular markers such as against SRC-3 has shown that loss of this coactivator
smooth muscle -actin, smooth muscle myosin heavy reduces the growth of cancer cells (Zhou et al., 2003).
chain, and myosin light chain kinase. From these data, Genetic ablation of SRC-3 clearly disrupts mammary
myocardin can be considered a dominant or master gland development, establishing a key role for this co-
regulator of smooth muscle cell differentiation. Mice activator in mammary biology through both gain and
lacking a functional myocardin gene die with vascular loss of function data (Xu et al., 2000).
malformations, apparently secondary to a failure to form SRC-2 has also been shown to be regulated recently,
functioning vascular smooth muscle cells (Li et al., 2003). specifically in the context of adipogenesis and energy
Somewhat surprisingly, cardiac structure and gene ex- balance. SRC-2, also known as TIF2, is induced in a
pression is normal in these mice, indicating that myocar- model of white fat cell differentiation, but the knockout
din is not required for heart development, perhaps due of this factor profoundly alters energy metabolism (Pi-
to the presence of myocardin-related factors with over- card et al., 2002). Mice lacking SRC-2 are leaner, contain
lapping or compensatory activities. less white adipose tissue, and have more active brown
The transcriptional activation function of myocardin fat. Interestingly, this thermogenic response to the lack
maps to its C-terminal domain; whether myocardin con- of SRC-2 may reflect differential effects of SRC-1 and
tains intrinsic chromatin-modifying activities or docks SRC-2 acting as secondary coactivators in complex with
PGC-1 (Picard et al., 2002).other proteins with such activities is not yet known
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Mechanism of Action of the SRCs transduction (Wu et al., 2002; Lin et al., 2002a; Hand-
schin et al., 2003).The SRCs are notable in that they function as both pri-
Given the necessity for very high oxidative metabolismmary and secondary coactivators (see PGC-1 below).
in heart, it is not surprising that PGC-1 (and its homologAll 3 SRCs can bind to nuclear receptors and other
PGC-1) are both expressed at high levels in the adulttranscription factors directly, and generally do so with
heart (Puigserver et al., 1998; Lin et al., 2002b). Experi-receptors in a ligand-dependent manner. The docking
ments in cultured cardiomyocytes indicate that PGC-to nuclear receptors utilizes multiple LXXLL motifs that
1 induces extensive mitochondrial biogenesis and anform amphipathic helices capable of recognizing the
increase in cellular respiration (Lehman et al., 2000).AF-2 domain of nuclear receptors (Xu and O’Malley,
However, unlike results observed in fat cells and skeletal2002). This is the domain which is controlled by ligand
muscle cells, the respiration induced by PGC-1 in heartbinding. The SRCs also contain a bHLH/PAS domain at
cells seems highly coupled. This implies that the func-their N termini. SRCs have an intrinsic activation domain
tion of PGC-1 here is mainly to provide ATP for heartthat can function in the context of Gal-4 fusion proteins
muscle contraction. Interestingly, PGC-1 expression is(Voegel et al., 1996). Importantly, this C-terminal region
reduced during experimental cardiac hypertrophy (Leh-contains histone acetyltransferase (HAT) activity (Chen
man and Kelly 2002), a process accompanied by a con-et al., 1997; Spencer and Jenster, 1997). Furthermore,
version from oxidative to more glycolytic metabolism.the SRCs recruit other coactivator proteins with HAT
Whether the change in PGC-1 expression drives thisactivity, such as CBP/p300 pCAF to a larger complex,
metabolic alteration and whether this change is adaptiveand these then also participate in chromatin modifica-
or maladaptive remains to be determined.tion (Xu and O’Malley, 2002).
PGC-1 also plays a prominent role in liver energyFinally, certain histone methyltransferases such as
metabolism. The liver is of central importance in theCARM1 and PRMT1 also interact with the SRCs (Chen,
metabolic adaptation to fasting, providing the body with1999, Koh et al., 2001), and these also augment SRC
an endogenous source of glucose via both glycogenoly-activity, presumably via methylation of certain histones.
sis and de novo glucose synthesis (gluconeogenesis).
It is generally believed that glycogenolysis is key in shortPGC-1
term fasting while gluconeogenesis kicks in duringPPAR- Coactivator-1 (now PGC-1) is a coactivator of
longer fasts and in starvation. Concomitant with themost nuclear receptors and several other transcription
activation of hepatic glucose production is a switch infactors (reviewed in Puigserver and Spiegelman, 2003;
liver metabolism from glucose to fatty acid oxidation toKnutti and Kralli, 2001). It is expressed in several tissues,
provide ATP for the liver’s own metabolic needs, andespecially those with very high oxidative metabolism,
to support gluconeogenesis. PGC-1 is induced in thesuch as heart, skeletal muscle, kidney, brown fat, brain,
fasted liver and is also elevated in untreated type 1 andand liver. This protein is highly inducible, typically when
type 2 diabetes (Yoon et al., 2001), where uncontrolledthere is a physiological need for a boost in oxidative
gluconeogenesis is also observed. When PGC-1 is in-metabolism in a given tissue. In brown fat, where PGC-
troduced into hepatocytes, most of the key features of
1 was first identified as a coactivator of PPAR, cold
the genetic program of the fasted state are induced:
exposure dramatically elevates its expression (Puig-
gluconeogenesis (PEPCK and glucose-6-phosphatase),
server et al., 1998). In fat cells, PGC-1 coactivates
increased mitochondrial electron transport, -oxidation
PPAR, PPAR, thyroid hormone receptor, and other of fatty acids, and ketogenesis. The activation of the
factors to execute a broad program of thermogenesis gluconeogenesis program by PGC-1 has been studied
that includes mitochondrial biogenesis and expression in some detail and involves coactivation of several tran-
of uncoupling protein 1 (UCP1), a biological uncoupler scription factors previously identified as key players on
of the mitochondrial oxidative phosphorylation system. the gluconeogenic promoters, especially the glucocorti-
PGC-1 is also highly expressed in skeletal muscle, coid receptor, FOXO1 and HNF-4 (Yoon et al., 2001;
with the greatest concentration occurring in the most Puigserver et al., 2003; Herzig et al., 2001). While consid-
oxidative fibers, termed type 1 or slow-twitch fibers. erably less is known about the function of PGC-1, it is
Transgenic expression of PGC-1 under the control of clear that this factor can also stimulate mitochondrial
the muscle creatine kinase promoter, which drives ex- biogenesis and respiration in muscle and liver cells (St.
pression in all skeletal muscle fiber types, stimulates Pierre et al., 2003; Lin et al., 2003). However, PGC-1
the appearance of more oxidative fibers, both type 1 does not appear to efficiently coactivate FOX01 or HNF-
and type 2a (Lin et al., 2002a). Interestingly, there is an 4, and does not stimulate the gluconeogenic gene
increase in mitochondrial number, as expected, but also program.
the expression of myofibrillar proteins that are charac- PGC-1 is induced in liver by agents that raise cyclic
teristic of the type 1 fibers. The muscles from these mice AMP, especially glucagons and catecholamines, and by
are also more resistant to fatigue, indicating that this is glucocorticoids (Yoon et al., 2001). These are classic
a bona fide switch of muscle fiber types. Several recent hormones that induce gluconeogenesis. While the tran-
papers have also shown that exercise in rodents or hu- scription factor CREB was known to be involved in the
mans induces PGC-1 (Norrbom et al., 2004; Baar et activation of gluconeogenesis and a CREB binding site
al., 2002; Terada et al., 2002; Goto et al., 2000), thus had been identified on the PEPCK promoter, more re-
placing it centrally in muscle fiber-type switching and cent data suggest that a major portion of CREB action
oxidative metabolism in response to exercise and physi- is via direct binding to the PGC-1 gene promoter (Her-
cal activity. This exercise-related induction of PGC-1 zig et al., 2001). Indeed, the suppressive effects of a
dominant-negative CREB allele on gluconeogenesis canappears linked to calcium-stimulated pathways of signal
Review
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be completely reversed by an adenoviral-mediated ex-
pression of PGC-1 in liver.
A loss of function mutation in vivo confirms the re-
quirement for PGC-1 in most of the functions described
above (Lin et al., 2004). PGC-1 knockout mice have a
partial lethality, but surviving mice are very cold sensi-
tive due in large measure to poor brown fat function.
Interestingly, while isolated knockout hepatocytes have
a severe loss of hormone stimulation of the genes of
gluconeogenesis, the gluconeogenic program in vivo is
locked in the “on” position, completely uncoupled from
feeding status. In contrast, expression of an siRNA di-
rected against PGC-1 in liver via adenoviral vectors
causes defective gluconeogenesis without any evi-
dence of compensation (Koo et al., 2004).
PGC-1 Mechanisms
No chromatin-modifying activities have been found in- Figure 2. Modulation of Transcriptional Activity by a Tissue-Spe-
cific Coactivatortrinsic to the PGC-1 molecule, but it has been shown
to dock many proteins that alter chromatin structure, Note that this coactivator can drive transcriptional activity over a
threshold needed for full gene activation.and to recruit other essential transcriptional compo-
nents. Deletion analysis of PGC-1 identified a major
N-terminal activation domain, which shows no homol-
ogy to known chromatin-modifying enzymes. Rather, while it is possible that dramatic regulation of coactiva-
this site recruits CBP/p300 and SRC-1, all of which have tor proteins is a relatively rare event, it is more probable
HAT activity (Puigserver et al., 1999). PGC-1 has also that it is a common mode of regulation that has not yet
been shown to dock the TRAP/DRIP/Mediator complex been fully appreciated. Certainly our experience with
near its C terminus, via direct binding of the TRAP220/ PGC-1 and- has suggested that regulation of coacti-
PBP subunit (Wallberg et al., 2003). PGC-1 also has vator levels in many tissues is far more common than
an autoinhibitory domain in its central region and this we had earlier imagined.
inhibition is relieved through phosphorylation by p38 Now that quantitative control at the coactivator level
MAP kinase (Puigserver et al., 2001; Knutti et al., 2001). is known to exist, it is worth considering why it might
This phosphorylation disrupts the binding of PGC-1 to exist and, more importantly, what this mode of regula-
p160 myb binding protein, a suppressor protein that tion implies for the control of biological function. The
may contain or dock a histone deacetylase (Fan et al., simplest scenario for understanding the function of a
2004). Thus, it is clear that PGC-1 represents a second- regulated coactivator is where it provides tissue or de-
ary coactivator protein, serving as a rather large scaffold velopmental specificity to a transcription factor that is
in the assembly of multiple large complexes that can more broadly expressed. As illustrated in the model in
modify chromatin. One important question is whether Figure 2, while the transcription factor is expressed in
the PGC-1 complexes are the same in all tissues and multiple tissues (A–E), only tissue C expresses the co-
all biological contexts, or whether there are components activator, which greatly boosts its transcriptional ac-
that are added or subtracted in different biological con- tivity.
texts. A very clear example of this is myocardin, which pro-
vides smooth muscle cell specificity to serum response
factor (SRF), which not only lacks smooth muscle-speci-Implications for Biological Regulation
at the Coactivator Levels ficity, but also is not even muscle cell-specific. While it
is at least formally possible that myocardin may also beIn principle, transcription of a particular gene can be
regulated by modulation of the activity of any compo- working through docking on other transcription factors
besides SRF, such interactions have not been identifiednent that affects this process. Why is it that alterations
in the amounts of transcription factors have been noted to date. Similarly, both OCA-B and FOG proteins func-
tion by providing developmental selectivity to the morein almost every possible biological process, while alter-
ations in coactivator proteins have been observed only widely distributed Oct and GATA factors, respectively.
Of course, even in the case of a regulatory schemerelatively recently? Certainly, a large part of the explana-
tion might be due to the fact that the techniques for controlled by coactivator modulation, as in Figure 2,
biological function is still sensitive to perturbations instudying DNA binding proteins (e.g., EMSA and DNA
footprinting assays) are simple to use, effective, and the structure or function of key transcription factor tar-
gets for this coactivator. A good example of this washave been available for many years. In contrast, there
is still no easy assay for determining which coactivator recently provided in a study of myocardin and growth
factor action (Wang et al., 2004). PDGF is a known sup-proteins are docking on a particular transcription factor
in a given cellular milieu. In addition, even when a coacti- pressor of smooth muscle differentiation, and also
causes the phosphorylation of ELK-1, a transcriptionvator protein is isolated biochemically or in a yeast two-
hybrid screen, it may not contain a signature motif that factor partner of SRF. Phosphorylation of ELK-1 in-
creases its binding to SRF and also displaces myocar-clearly announces its function as a coactivator. Thus,
Cell
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Figure 3. Hypothetical Biological Program
Comprised of Intersecting Biochemical
Pathways
The three pathways are controlled by tran-
scription factors E1–E3. This situation, com-
mon in biology, can be portrayed as separate
pathways that utilize some of the same mole-
cules as precursors and products, as in (A).
However, this can also be portrayed, kinet-
ically, as a single pathway, as in (B).
din, thus inhibiting smooth muscle gene expression is largely unexplored territory. However, this phenome-
non is likely to be very important in explaining how cer-(Wang et al., 2004). This illustrates the dynamic nature
of these multicomponent systems. tain coactivators drive only a limited subset of biologi-
cal programs.While it is obvious that the model of coactivator func-
tion shown above can yield a large increase in transcrip- A situation even more complex arises when modula-
tion of coactivator amounts or activities can allow thetional activity through a given DNA binding factor, it is
not immediately apparent how it can yield qualitative as construction of biological program through simultane-
ous modulation of several different transcription factors.opposed to quantitative responses. For example, even
in the absence of growth factor signaling, myocardin A clear example of this, introduced above, is the regula-
tion of the fasted liver response by PGC-1. As an organ-does not activate all genes that have SRF sites in their
promoters, but selectively activates smooth muscle- ism fasts or starves, there is a dramatic shift from the
utilization of exogenous nutrients to a total reliance onselective promoters. Theoretically, this can be accom-
plished in at least two ways: first, if the process of gene stored energy deposits. Fat is a very convenient (and
efficient) storage form of energy, but it is wholly inade-activation for a certain set of genes governing a particu-
lar biological response requires a threshold of positive quate as a direct energy source for many tissues, nota-
bly the central nervous system which requires glucose.signals before it can be switched into an “on” position,
a coactivator may boost a signal above this level (as Because mammals cannot directly convert fat to glu-
cose, the liver reduces its own glucose metabolism dur-shown in Figure 2). Second, there may be promoter
selectivity to coactivator action; some promoters may ing fasting and shifts to the -oxidation of fatty acids
for the generation of ATP. The genes of -oxidation ofhave a strict requirement for a certain coactivator in
order to achieve gene activation. This is still a murky fatty acids are mainly controlled by PPAR, PPAR/,
and ERR, all targets of PGC-1 coactivation. However,area but there are data to suggest that coactivators can
be more than simple quantitative effectors of a given as these fuels are oxidized, there is an increased need
for mitochondrial electron transport activity, in order tofactor through all of its binding sites. A clear-cut example
of this is the coactivation of PPAR binding sites by actually generate ATP. The oxidative phosphorylation
pathway (OXPHOS) is controlled by ERR, and an addi-PGC-1 in adipose cells. PGC-1 is expressed preferen-
tially in brown fat cells, as is UCP-1, while the aP2 gene tional set of transcription factors, NRF-1 and NRF-2
(GABPA/B), which are also coactivated by PGC-1is expressed in all adipose lineages, white and brown.
Both the aP2 and UCP-1 genes have well-characterized (Mootha et al., 2004; Schreiber et al., 2004). Finally, as
noted above, the genes of gluconeogenesis (e.g.,PPAR binding sites and both white and brown cells
express large amounts of PPAR protein. Activation of PEPCK and glucose-6-phosphatase, which produce
glucose from substrates like glycerol, alanine and lac-PPAR with agonist ligands increases the expression
of both genes. However, when PGC-1 is introduced tate), are largely controlled by the docking of PGC-1 on
the GR, FOXO1, and HNF-4. Thus, a coherent biologicalinto white fat cells, UCP-1 gene expression increases,
while aP2 expression does not; in fact it decreases mod- program can be activated, that would presumably other-
wise be difficult to coordinate.estly (Puigserver et al., 1998). This selective activation
of only certain promoters containing a binding site for This “soft-wiring” integration of different pathways via
coactivator action, as opposed to “hard-wiring” thema given transcription factor would strongly suggest that
the coactivator protein is playing a crucial role in “select- together via one set of transcription factors, has one
obvious adaptive advantage: it allows for independenting” the subset of genes that make up a given biological
program. Whether all regulated coactivators exercise a regulation within the same tissue or in different tissues.
For example, skeletal muscle must have the ability todegree of promoter selectivity and how this is executed
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Figure 4. Production of End-Product P, as a
Function of Simultaneous Equal Increases in
Transcription Factors E1–E3 or an Equivalent
Increase in Each Factor Individually
modulate the -oxidation of fatty acids and the mito- activator level has clear kinetic implications that are
worth considering. According to the older concept ofchondrial OXPHOS system, to generate ATP, especially
in response to chronic physical activity. However, the the “rate-limiting step,” only modulation of the slowest
step in a biological pathway or process can speed upskeletal muscle never (as far as is known) utilizes ATP
for gluconeogenesis; rather, this high-energy compound the rate of output of that pathway. However, recent
experimental and theoretical studies have indicated thatis used primarily to support muscle contraction. This
results from the fact that skeletal muscle does not ex- alteration of many steps in the same pathway can dra-
matically change the output of an entire pathway farpress at high levels the transcription factors linked to
gluconeogenesis (FOXO1 and HNF-4), and PGC-1 is more than the modulation of any one step alone. Thus,
different steps in a biochemical pathway are referred tonot induced in muscle upon fasting. Rather, it is induced
as a consequence of physical activity, and resulting as having a given “coefficient of control” (Heinrich and
Rapoport, 1974; Heinrich and Shuster, 1996; Fell, 1997).calcium fluxes in myotubes.
This is relevant to coactivator proteins because they
have the ability to change many linked steps and indeed,Kinetic Considerations
In addition to the coordination of individual processes linked pathways, simultaneously.
Consider 3 linked pathways, 1–3, where pathway 1according to physiological state, regulation at the co-
Figure 5. Production of the Intermediate
Product, X1, as a Function of Simultaneous
Increases in Transcription Factors E1–E3, or
Increases in Each Factor Individually
Note that only simultaneous increase in all
transcription factors in these pathways can




is controlled by transcription factor E1, pathway 2 is mon or unusual feature of biological programs. This
question may remain largely unanswered until bettercontrolled by transcription factor E2, and pathway 3
is controlled by transcription factor E3 (Figure 3). It is general methods are established that identify which co-
activators are engaged with particular transcription fac-assumed here that the intrinsic rate constants of the
enzymes controlled by these transcription factors are tors in physiological states of interest. The explosion in
our knowledge about transcriptional control in develop-identical. It is also assumed that all substrate levels (S,
X1, X2) are below the Kms of the respective steps, though ment, differentiation, and physiology correlated tightly
with the advent of techniques, such as EMSA and DNAthe results would be essentially unaltered even at higher
substrate levels. footprinting assays, that readily allowed the identifica-
tion of transcription factors that bound to DNA se-Furthermore, assume that the product of pathway 1,
X1, is required in pathway 2 to produce X2 and that, in quences that were associated with regulatory function.
At the present time, regulation via coactivator modula-turn, is required by pathway 3 to produce the final prod-
uct P. Again, using the hepatic fasting response as a tion must be considered as a realistic possibility where
key cis-acting DNA elements involved in a particularconcrete example, the original substrate S might be
fatty acids, while X1 might be NADH derived from the pathway are identified, but the cognate DNA binding
proteins are not themselves regulated. This was true for-oxidation of these fatty acids (pathway 1), X2 might
be ATP derived from the OXPHOS system (pathway 2) most of the examples cited in this review. Of course,
the unregulated transcription factors can be valuableand P would be glucose derived from the gluconeogenic
pathway (3). As shown in the right hand side of Figure tools for the identification of the relevant and perhaps
regulated coactivators, in either biochemical purifica-3, this can also be represented as a more classical linear
pathway, at least with regard to the specific substrates tions or genetic screens. Looking toward the future, one
can imagine eventually combining large-scale proteo-and products mentioned above. Figure 4 illustrates the
effects on production of final product P by increasing mic data sets that map global protein-protein interac-
tions (Li et al., 2004), with cell and tissue transcriptionone or all of the transcription factors in this path, making
the simple assumption that an increase in transcriptional profiling data to quickly ascertain whether a given tran-
scription factor has an interacting partner which is highlyfactor activity will result in a proportional increase in
catalytic activity of the pathway under its control. The regulated in a setting of interest. However, at this mo-
ment we are mostly left with the slower approachesassumptions and details of these calculations are de-
tailed in Appendix 1 (available as Supplemental Data at used to identify the known regulated coactivators.
The “soft-wiring” nature of coactivator control alsohttp://www.cell.com/cgi/content/full/119/2/157/DC1/).
These analyses illustrates the overwhelming effect of has the potential promise of allowing the unbundling of
linked biological processes in ways that could be usefulsimultaneously increasing each transcription factor ac-
tivity by an equivalent amount, as opposed to changing therapeutically. For example, glucocorticoids are among
the most powerful immunosuppressive agents known,the activity of only one factor. Having the activities of
factors E1–3 augmented by the same coactivator will have but their chronic use clinically is limited by a number
of unwanted side effects, including the stimulation ofthis effect. Relying on coactivation of linked pathways
can function more like a simple rheostat or switch with gluconeogenesis. This has a diabetogenic effect over
the long term. However, since the GR functions in gluco-regard to the final product P, with greater dynamic range
and a much faster rate. One less obvious but important neogenesis, at least in part, through the docking of
PGC-1, a GR agonist that allows docking of other co-implication that comes from this model relates to meta-
bolic intermediates, as shown in Figure 5. activators but does not facilitate PGC-1 binding might
represent a novel therapeutic entity. Indeed, such anElevation of a single transcription factor is not only
inefficient at producing more P, but it leads to great early stage drug has been described (Coughlan, 2003)
and serves as an important proof of principle that thechanges in specific pathway intermediates. Restricting
our attention, for example, only to product X1 (from Fig- development of drugs activating or inhibiting the dock-
ing of specific coactivator proteins is indeed plausible.ure 3), simultaneous coactivation of transcription factors
E1–3 will cause no change in the steady-state level of X1. While such approaches might have their own set of
toxicity and side-effect issues, they hold out very excit-However, increases in E1 alone would raise X1 levels
while activation of either E2 or E3 would decrease the ing promise.
concentrations of X1. When one considers that X1 could
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